We have devised a barcoding strategy to recapitulate cancer evolution through the emergence of subclonal mutations of interest, whose effects can be monitored in a dynamic manner. This approach can be easily adapted for a variety of applications, including combined modeling of multiple mechanisms of drug resistance or repair of oncogenic driver mutations in addicted cancer cells.

Original languageEnglish
Article numbere1227894
JournalMolecular and Cellular Oncology
Issue number6
StatePublished - 1 Nov 2016


  • ALK
  • APC
  • CRISPR/Cas9
  • EGFR
  • TP53
  • genetic barcoding
  • non-small cell lung cancer
  • resistance
  • tumor heterogeneity


Dive into the research topics of 'Modeling intratumor heterogeneity through CRISPR-barcodes'. Together they form a unique fingerprint.

Cite this